Daiichi Sankyo appoints two new executives

Daiichi Sankyo has announced two new executive appointments following the departure of John Gargiulo, the president and chief executive officer (CEO) of the US-based Daiichi Sankyo Inc.

Dr Glenn Gormley has been named corporate president and chairman of Daiichi Sankyo Inc and will also continue in his existing roles as president of Daiichi Sankyo Pharma Development, global head of research and development and senior executive officer of the Daiichi Sankyo group.

Meanwhile, Greg Barrett has been appointed as the new acting head of the commercial division of Daiichi Sankyo Inc in the US, with both appointments having taken effect on October 3rd 2013.

Mr Barrett will be responsible for leading Daiichi Sankyo's US commercial operations, including marketing, sales and supply chain operations in the North American territory.

These two appointments coincide with the exit of former president, CEO and commercial division head Mr Gargiulo, who left the company earlier this month.

Founded in 2005, the Daiichi Sankyo group is headquartered in Tokyo and is known for medicinal brands such as Olmetec, Efient and Lixiana.